Tuberculosis Clinical Trial
— Doxy-TBOfficial title:
Doxycycline and the Modulation of Host Immunopathology in Human Pulmonary Tuberculosis: A Pilot Study
Verified date | May 2016 |
Source | National University Hospital, Singapore |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pulmonary cavitation, a hallmark of tuberculosis (TB), is the site of high mycobacterial
burden leading to disease transmission. The cause of tissue destruction leading to cavitation
in TB is primarily due to the host inflammatory response. A matrix degrading phenotype
develops in TB, in which the activity of host proteolytic enzymes, specifically matrix
metalloproteinases (MMPs) is unopposed by their specific Tissue Inhibitors of
Metalloproteinases (TIMPs), thus driving tissue destruction and cavitation in TB. This tissue
destruction causes morbidity and mortality. MMP inhibition with doxycycline has shown to
improve lung function in patients with chronic lung diseases but its use in TB is unclear.
We hypothesise that the MMP inhibitor doxycycline will reduce tissue destruction in human
pulmonary tuberculosis.
Specific aims:
- To investigate the MMP and TIMP secretion and gene expression in M. tuberculosis (M.tb)
- infected primary neutrophils and monocytes from healthy volunteers taking doxycycline.
- To investigate the intracellular signaling pathways modulated by doxycycline
- To investigate the effects doxycycline has on biological markers of tissue destruction
in TB patients
- To assess the tolerability and side effects of doxycycline with concurrent standard TB
therapy
Status | Completed |
Enrollment | 40 |
Est. completion date | June 2017 |
Est. primary completion date | June 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 70 Years |
Eligibility |
Healthy Volunteers 10 volunteers will be recruited comprising 5 females and 5 males. Inclusion criteria: 1. No known medical conditions 2. Aged 21 years to less than 70. Exclusion criteria: 1. Unable to give informed consent 2. Prisoners 3. Pregnancy or nursing 4. On medication or oral contraceptives 5. Any concurrent illness, such as influenza TB patients Inclusion criteria: Patients should meet all criteria 1. Patients receiving = 7 days of TB treatment or about to start standard combination TB treatment 2. Confirmed pulmonary TB with positive acid-fast bacilli smear and/or positive TB GeneXpert test and/or culture results 3. Chest radiograph demonstrating pulmonary involvement 4. Aged 21 years to less than 70 Exclusion criteria: 1. HIV co-infection 2. Previous pulmonary TB 3. Severe, pre-existing lung disease such as pulmonary fibrosis, bronchiectasis, Chronic obstructive pulmonary disease and lung cancer 4. Pregnant or breast feeding 5. Allergies to tetracyclines 6. Patients on retinoic acid, neuromuscular blocking agents and pimozide which may increase risk of drug toxicity 7. Autoimmune disease and/or on systemic immunosuppressants 8. Unable to provide informed consent 9. Haemoglobin < 8 g/dl 10. Creatinine 2 times upper limit of normal (ULN) 11. Alanine transaminase >3 times ULN 12. Use of any investigational or non-registered drug, vaccine or medical device other than the study drug within 182 days preceding dosing of study drug, or planned use during the study period 13. Enrolment in any other clinical trial involving a systemic drug or intervention involving the lung 14. Evidence of severe depression, schizophrenia or mania 15. Principal investigator assessment of lack of willingness to participate and comply with all requirements of the protocol, or identification of any factor felt to significantly increase the participant's risk of suffering an adverse outcome |
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore | A*Star, National University, Singapore, Tan Tock Seng Hospital |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of serum marker Procollagen III N-terminal peptide (PIIINP) from day 0 to day 14 in TB patients | Day 0 and Day 14 | ||
Secondary | Number of participants with treatment-related adverse events | day 0 to day 56 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |